Chemoimmunotherapy for relapsed/refractory Mature B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children (SPARKLE Trial): Initial Safety, PK, and Efficacy
Author Type(s)
Faculty
Document Type
Abstract
Publication Date
6-2019
DOI
10.1002/hon.27_2629
Journal Title
Hematalogical Oncology
Department
Pediatrics
Second Department
Health Behavior and Community Health
Recommended Citation
Burke, G. A., Beishuizen, A., Bhojwani, D., Burkhardt, B., Minard-Colin, V., Norris, R., Kabickova, E., Pinarli, F. G., Tacyildiz, N., de Jong, J., Liu, G., Howes, A., Nottage, K., Salman, M., de Trixe, X. W., & Cairo, M. (2019). Chemoimmunotherapy for relapsed/refractory Mature B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children (SPARKLE Trial): Initial Safety, PK, and Efficacy. Hematalogical Oncology, 37 (52 Suppl.), 57-59. https://doi.org/10.1002/hon.27_2629
